Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
CORRECTION: Weifa ASA: Record first-quarter revenues driven by organic growth | ||
By: Nasdaq / GlobeNewswire - 27 Apr 2017 | Back to overview list |
|
Oslo, 27 April 2017
EBITDA was NOK 21.2 million (NOK 16.5 million) for the first quarter after NOK 1.0 million (NOK 5.5 million) in cost of employee options and other costs. The EBITDA margin adjusted for these costs was 22.3% (22.8%). Weifa's portfolio of long-established brands maintained a high market share in all key segments during the quarter. "We maintained a steady pace into 2017 with record first-quarter revenues. The launch of Nazamér Menthol and Paracetduo effervescent tablets extended our innovation track record, which together with rising demand for our main products are a key driver for our long-term growth," says CEO Kathrine Gamborg Andreassen.
Weifa will give a presentation today at 08:30 CET at Felix Konferansesenter, Bryggetorget 3, Oslo, Norway. CEO Kathrine Gamborg Andreassen and CFO Simen Nyberg-Hansen will represent the company. The presentation will also be webcast live and can be accessed directly from:
Please find the report and presentation for the first quarter enclosed. The report and presentation will also be made available on www.weifa.no /investor . For further information, please contact:
Kathrine Gamborg Andreassen
Simen Nyberg-Hansen
Weifa is Norway's leading consumer health company. We supply real value through medicines, lifestyle products and solutions that address the essential needs of consumers, customers and professional partners. Weifa was founded in 1940 and now employs about 30 highly qualified people at our headquarters in Oslo. The company has a strong position in Norway and is the market leader in pain relief, with well-established brands such as Paracet and Ibux. We are also present in other key areas such as dietary supplements and treatment for colds and respiratory problems. Weifa is listed on the Oslo Børs (ticker WEIFA). For further information, please visit: www.weifa.no
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Weifa ASA via GlobeNewswire
HUG#2099467
|
||
|
||
Copyright 2017 Nasdaq / GlobeNewswire | Back to overview list |